Novo Nordisk: Financial report for the period 1 January 2013 to 30 September 2013. Increased operating profit by 10% in the first nine months of 2013

BAGSVAERD, Denmark, Oct. 31, 2013 (GLOBE NEWSWIRE) --

Sales growth of 8% driven by Victoza(®), Levemir(®) and NovoRapid(®) Sales increased by 13% in local currencies and by 8% in Danish kroner to DKK 61.9 billion. - Sales of modern insulins increased by 15% (10% in Danish kroner). - Sales of Victoza(®) increased by 28% (24% in Danish kroner). - Sales in North America increased by 20% (17% in Danish kroner). - Sales in International Operations increased by 15% (8% in Danish kroner). Company announcement No 68 / 2013: http://hugin.info/2013/R/1739405/583808.pdf [HUG#1739405] CONTACT: CONTACTS FOR FURTHER INFORMATION Media: Mike Rulis +45 4442 3573 mike@novonordisk.com Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com Investors: Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com Frank Daniel Mersebach +45 3079 0604 fdni@novonordisk.com Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com Daniel Bohsen +45 3079 6376 dabo@novonordisk.com Jannick Lindegaard (US) +1 609 786 4575 jlis@novonordisk.comSource:Novo Nordisk A/S